Sodium orthovanadate ≥96%, Powder

Supplier: MP BIOMEDICALS (FKA ICN BIOMED

0215966410 0215966425 0215966480
IC15966410EA 55.88 USD
IC15966410 IC15966425 IC15966480
Sodium orthovanadate ≥96%, Powder
Sodium orthovanadate

Inhibits ATPase, alkaline phosphatase and tyrosine phosphatase. Decavanadate, which is formed at acidic pH, inhibits inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release from endocrine cells and blocks IP3 binding to its receptor in brain tissue.


Sodium Orthovanadate is used in the diabetes study. Inhibits ATPase, alkaline phosphatase and tyrosine phosphatase. Decavanadate, which is formed at acidic pH, inhibits inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release from endocrine cells and blocks IP3 binding to its receptor in brain tissue.


Soluble in water (50 mg/mL- clear to hazy, colorless to faint yellow solution).


Sodium Orthovanadate is used in the diabetes study. Inhibits ATPase, alkaline phosphatase and tyrosine phosphatase. Decavanadate, which is formed at acidic pH, inhibits inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release from endocrine cells and blocks IP3 binding to its receptor in brain tissue.

Formula: Na₃O₄V
MW: 183.91 g/mol
MDL Number: MFCD00003511
CAS Number: 13721-39-6

Order Now

SPECIFICATIONS

Environmentally Preferable

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR